Homarylamine

Homarylamine (INN;[1] also known as 3,4-methylenedioxy-N-methylphenethylamine and MDMPEA) is an antitussive (anti-cough) drug which was patented in 1956 by Merck & Co.,[2] but has never been used medically as such.

Homarylamine
Clinical data
Other names1,3-benzodioxolyl-N-methyl-5-ethanamine;
3,4-methylenedioxy-N-methyl-2-phenylethylamine;
Norlobivine
Routes of
administration		Various
Identifiers
IUPAC name
  • 2-(1,3-Benzodioxol-5-yl)-N-methylethanamine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC10H13NO2
Molar mass179.219 g·mol−1
3D model (JSmol)
SMILES
  • CNCCC1=CC2=C(C=C1)OCO2
InChI
  • InChI=1S/C10H13NO2/c1-11-5-4-8-2-3-9-10(6-8)13-7-12-9/h2-3,6,11H,4-5,7H2,1H3
  • Key:OPJOMVMFYOUDPK-UHFFFAOYSA-N
  (verify)

Chemically it is a substituted phenethylamine. It is the N-methylated analog of methylenedioxyphenethylamine (MDPEA).

Methylenedioxyphenethylamine (MDPEA) for comparison

Reactions

Reaction of homoarylamine with formaldehyde gives hydrastinine.

See also
  • Hydrastine, an alkaloid derivative of homarylamine

References
  1. "International Non-Proprietary Names for Pharmaceutical Preparations" (PDF). Chronicle of the World Health Organization. 12 (3). 1958.
  2. U.S. Patent 2,820,739



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.